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Hepatitis B virus (HBV) chronically infects 400 million people
worldwide and is a leading driver of end-stage liver disease and
liver cancer. Research into the biology and treatment of HBV
requires an in vitro cell-culture system that supports the infection
of human hepatocytes, and accurately recapitulates virus–host
interactions. Here, we report that micropatterned cocultures of
primary human hepatocytes with stromal cells (MPCCs) reliably
support productive HBV infection, and infection can be enhanced
by blocking elements of the hepatocyte innate immune response
associated with the induction of IFN-stimulated genes. MPCCs
maintain prolonged, productive infection and represent a facile
platform for studying virus–host interactions and for developing
antiviral interventions. Hepatocytes obtained from different hu-
man donors vary dramatically in their permissiveness to HBV in-
fection, suggesting that factors—such as divergence in genetic
susceptibility to infection—may influence infection in vitro. To es-
tablish a complementary, renewable system on an isogenic back-
ground in which candidate genetics can be interrogated, we show
that inducible pluripotent stem cells differentiated into hepato-
cyte-like cells (iHeps) support HBV infection that can also be en-
hanced by blocking interferon-stimulated gene induction. Notably,
the emergence of the capacity to support HBV transcriptional ac-
tivity and initial permissiveness for infection are marked by dis-
tinct stages of iHep differentiation, suggesting that infection of
iHeps can be used both to study HBV, and conversely to assess the
degree of iHep differentiation. Our work demonstrates the utility
of these infectious systems for studying HBV biology and the virus’
interactions with host hepatocyte genetics and physiology.
HBV persistence | innate immunity | viral hepatitis
Hepatitis B virus (HBV) is a small 3.2-kb DNA virus thatselectively infects hepatocytes in the human liver (1). The
global disease burden is large, with ∼400 million people chron-
ically infected worldwide, of whom about one-third will develop
severe HBV-related complications, such as cirrhosis and liver
cancer. Lifelong treatment is often required because of the stable
nature of viral episomal DNA, known as covalently closed cir-
cular DNA (cccDNA), which maintains basal levels in infected
cell nuclei even upon nucleos(t)ide inhibitor treatment. To date,
HBV research has been hampered by a distinct lack of robust
infectious model systems that both support productive HBV in-
fection and accurately mimic virus–host interactions. Recently,
the bile acid pump sodium taurocholate cotransporting poly-
peptide (NTCP) has been identified as a receptor for both HBV
and hepatitis D virus (2), and overexpression of NTCP in hep-
atoma cell lines renders them susceptible to HBV infection.
However, hepatoma cells are known to be defective in many
cellular pathways implicated in the innate immune response
(3, 4), metabolism (5), and cell proliferation (6), which may
contribute to published contradictory evidence regarding the
extent to which HBV activates the innate immune response, and
the importance of this response in curtailing infection (for a re-
view, see ref. 7).
As the sole host cell infected by HBV in vivo, primary adult
human hepatocytes represent the gold-standard for studying
HBV interactions with the host. Prior studies have shown that
primary human hepatocytes support HBV infection, although
infection is usually not robust even upon supplementation of
cell-culture medium with dimethyl sulfoxide (8) or polyethylene
glycol (9). Moreover, primary human hepatocytes rapidly lose
their hepatic phenotype shortly after isolation from the in vivo
microenvironment (10, 11). We have previously developed
a miniaturized system in which primary hepatocytes are orga-
nized in micropatterned colonies and surrounded by supportive
stromal cells, providing hepatocytes with the necessary homo-
typic and heterotypic cell–cell interactions to promote long-term
maintenance of their hepatic function (12). This micropatterned
coculture (MPCC) system maintains hepatocyte phenotype and
function over several weeks and has been shown to support ro-
bust infection with hepatitis C virus (HCV) and Plasmodium
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falciparum and vivax malaria (13, 14). We hypothesized that this
system would be ideal for modeling HBV infection in vitro.
Beyond its potential utility for assessing virus–host inter-
actions, studying the role of host factors in the MPCC system is
complicated by limited availability and variability between donor
hepatocytes. As a complementary approach that enables more
facile genetic manipulation on an untransformed and isogenic
hepatocyte background, we also sought to establish robust HBV
infection in induced pluripotent stem cell (iPSC)-derived hepa-
tocyte-like cells (iHeps) (15, 16). These cells have demonstrated
their utility for modeling inherited metabolic disorders (17), in-
corporating genetic manipulations (18), and supporting infection
with HCV (19–21). During iHep generation, the progression of
differentiation is characterized by the sequential emergence of
various hepatocyte-specific host factors known to play a role in
the HBV life cycle, such as the transcription factor HNF4α and
the nuclear receptor RXR (22). We show that permissiveness to
HBV infection likewise progresses in a differentiation stage-
specific manner. Thus, in this paper we use a system of stabilized
primary hepatocytes for disease modeling to establish HBV in-
fection in vitro and explore the use of directed differentiation of
iPSCs to demonstrate that they serve as a suitable host pop-
ulation for the study of HBV and host–virus interactions.
Results
Micropatterned Human Hepatocytes Stably Express the HBV Receptor
for Weeks in Culture. It has been hypothesized that primary human
hepatocytes lose their permissiveness to HBV infection because
of down-regulation of NTCP receptor expression upon isolation
and subsequent culture (2). Our MPCCs of primary human
hepatocytes and stromal fibroblasts (J2-3T3 fibroblasts, or J2s)
maintain hepatocyte functions as well as polarity and promote
the accurate localization of membrane proteins to hepatocytes’
basolateral and apical domains (12). Although many distinct
hepatocyte culture models have been explored in the literature, a
telling control to probe the importance of tissue microarchi-
tecture is seeding similar cellular constituents in a random con-
figuration (random coculture, RCC) (Fig. 1A). NTCP was readily
detected on the plasma membrane by immunostaining of hep-
atocytes in MPCCs (Fig. 1B), whereas the NTCP level at 18 d
postplating was drastically reduced in RCCs (Fig. 1 B–D). Be-
cause viral spread is dependent upon consistent expression of the
entry receptor, we analyzed NTCP levels over a course of 14 d,
and found that NTCP protein and mRNA levels remained stable
over time (Fig. S1A). These results establish the capacity of the
MPCC format to maintain expression of the HBV receptor,
NTCP, in vitro.
Fig. 1. HBV infection in micropatterned primary human hepatocytes is augmented by innate immune inhibition. (A) MPCC vs. RCC schematic. Hepatocytes in
pink, fibroblasts in purple. (B) NTCP immunostaining: white circle marks hepatocyte island boundary. (Scale bar, 100 μm.) (C) NTCP Western blot. (D) NTCP
quantitative RT-PCR (qRT-PCR; mean ± SEM, n = 3). (E) Schematic of viral life-cycle readouts used. (F, Left) ELISA for HBsAg, expressed as a mean ± SEM (n = 3),
secreted into supernatant between 14 and 16 dpi; (Center) HBV 3.5-kb mRNA expression (one cell pellet per condition) at 16 dpi; (Right) Copies of cccDNA at
16 dpi, expressed as an average of biological duplicates ± range. (G) HBc immunostaining of MPCCs at the indicated days postinfection. Isotype-matched
negative control shown. (Scale bars, 50 μm.) (H) Time course of HBV infection in MPCCs. (Left panels) HBsAg and HBeAg levels (average of triplicates) in
supernatant; (Center) cccDNA levels; (Right panels) qRT-PCR for HBV 3.5-kb mRNA and total mRNA. Expression relative to DMSO-treated samples 7 dpi, one
pellet per condition per experiment, verified across independent experiments. Dotted lines: limit of quantification (qPCR), cut-off (ELISA).
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MPCCs Support Productive HBV Infection. Given the importance of
the MPCC format for maintaining expression of the HBV re-
ceptor as well as other hepatocyte functions (Fig. S1 B and C),
we next investigated whether MPCCs support HBV infection.
We assayed various viral life-cycle stages, including viral gene
expression, reflected by HBV surface antigen (HBsAg) secretion
and 3.5-kb mRNA (the main HBV transcript) production, and
the presence of the viral transcription template cccDNA, con-
sidered a hallmark of productive infection (Fig. 1E). We found
that HBV derived from human infectious serum infects human
hepatocytes more efficiently in MPCCs than RCCs (Fig. 1F).
Furthermore, MPCCs support productive infection throughout
the culture period of nearly 3 wk, based on immunostaining for
HBV core (HBc) protein (Fig. 1G).
Based on previous data that the innate immune response can
restrict HCV infection in hepatocytes (23), we explored pre-
treatment of MPCCs or RCCs with a broad-spectrum Janus ki-
nase (JAK) inhibitor (JAKi), known to interfere with a major
pathway of the innate immune axis by dampening expression of
IFN-stimulated genes (ISGs) (24), in an attempt to elicit en-
hanced HBV replication efficiency. With the addition of JAKi,
we observed more robust HBV infection in MPCCs (Fig. 1H)
and detected cccDNA almost exclusively in this format (Fig. 1F,
Right). Augmentation of HBV infection was also observed upon
introduction of an inhibitor of TANK-binding kinase 1 (TBK1),
an upstream activator of the IFN response pathway, although
JAKi was more efficient in maintaining cccDNA following in-
fection (Fig. S2). Collectively, these results suggest that the
MPCC format supports the maintenance of productive infection
over time in primary human hepatocytes, and that inhibition of
major pathways of the hepatocyte innate immune response
enhances infection in this system.
Temporal Expression of ISGs Following HBV Infection. In response to
intracellular pathogen sensors, an innate immune pathway typi-
cally activates a set of ISGs, leading to autocrine/paracrine
signaling by interferons. Based on our observation that addition
of a JAK pathway inhibitor improved HBV infection in MPCCs,
we hypothesized that the innate immune response may induce
antiviral ISGs, at least in culture. To assay for this response, we
incubated MPCCs with HBV infectious serum and analyzed the
relative expression of type I IFNs, IFN-α, and IFN-β, as well as
two genes implicated in type III IFN response, over the next 16 d
(Fig. 2, Left). Both IFN-α and IFN-β were induced mainly late
during the course of infection, although a modest induction
(>two-fold) was detected as early as 12 h postinfection. The
expression of a variety of ISGs implicated in antiviral responses
were also detected following HBV infection, with a range of
kinetic patterns, including several that function as sensors and
transducers of these pathways (Fig. 2, Center), and a selection of
antiviral effectors (Fig. 2, Right). Consistent with our hypothesis,
we found that blunting the innate immune response with JAK
inhibition blocked the expression of many downstream ISGs but
had no significant effect on the expression of either IFN-α or
IFN-β, which are regulated upstream of JAK-STAT signaling.
We note that some exhibit a biphasic elevation over time, pos-
sibly representing reinfection events or expression in response to
the emergence of later stage viral components. Importantly, ISG
induction was dependent on productive HBV infection, because
pretreatment of MPCCs with the HBV inhibitor entecavir largely
abolished the induction of most early- and late-stage interferons
and downstream ISGs (Fig. S3A).
Interestingly, although productive infection could be clearly
detected in NTCP-expressing HepG2 hepatoma cells, as evi-
denced by production of HBV 3.5-kb mRNA (Fig. S3B, Left), no
significant ISG induction was observed in these cells compared
with HBV nonpermissive HepG2 cells (Fig. S3B, Right). These
data suggest that either HBV sensors or key transducers in this
sensing pathway are defective in hepatoma cells, highlighting
a distinct opportunity of the MPCC system in terms of its po-
tential for studying virus-host interactions in HBV infection.
MPCCs Offer the Potential to Study Antiviral Candidates. Following
the demonstration that the MPCC format can support HBV
infection, we asked whether the platform could be applied for
use as an anti-HBV drug-testing tool. As proof-of-principle, we
incubated MPCCs with HBV-infected serum with or without
concomitant treatment with the HBV reverse-transcriptase in-
hibitor entecavir, or an alternate antiviral, IFN-β. The addition
of prophylactic entecavir or IFN-β to MPCCs abrogated HBV
infection, as indicated by a sharp decrease in the secretion of
both HBV DNA and HBsAg into the medium over time (Fig.
3A). Consistent with these findings, levels of cellular 3.5-kb
mRNA and cccDNA were also dramatically reduced in infected
cells pretreated with IFN-β or with entecavir, as long as 21 d
postinfection (dpi) (Fig. S4).
Having established that MPCCs can successfully model pro-
phylactic drug protection against HBV, we assayed their poten-
tial utility to model a more clinically relevant regimen by starting
treatment with IFN-β or entecavir 7 d after establishing HBV
infection. Both treatments significantly reduced HBV DNA se-
cretion into the medium by preinfected MPCCs, indicating an
efficient inhibition of HBV replication (Fig. 3B). In contrast,
only IFN-β, but not entecavir, abolished the levels of 3.5-kb
mRNA and cccDNA observed at 16 dpi (9 d after initiating drug
treatment), consistent with published differences in the capacity
of reverse-transcriptase inhibitors versus interferons to promote
cccDNA elimination (25). Collectively, these results demonstrate
that the MPCC system can serve as a platform for studying the
efficacy and mechanism of action of diverse antiviral agents, and
has the potential to be expanded to a medium-to-high through-
put drug-discovery tool (13, 26).
Fig. 2. Temporal induction of ISGs in HBV infected MPCCs. Primary human
hepatocyteMPCCs were either mock- or HBV-infected with concomitant JAKi or
DMSO (vehicle control) treatment. RNA expression was analyzed for the in-
dicated ISGs at 12 h, 24 h, 48 h, 72 h, 7 d, 11 d, and 16 d postinfection and
reported relative to the mock-infected cells, expressed as a mean ± SEM (n = 3).
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Hepatic Donors That Share a Differentiated Phenotype in Vitro
Exhibit Variable HBV Permissiveness. To establish a viable drug
testing platform, it is essential to identify a source of re-
producibly infectible hepatocytes. The advent of cryopreserved
human hepatocytes partially achieves this goal, in terms of of-
fering a uniform donor source. To examine the importance of
host variability in HBV infection of MPCCs, we used MPCCs
seeded with hepatocytes derived from different hepatic donors
(HD) (Table S1) and incubated them with patient-derived HBV
infectious serum. Analyzing markers of productive infection
revealed a wide variation between donors, with hepatic donor 4
(HD4) showing the most robust HBsAg production (Fig. 3C) and
cccDNA formation (Fig. 3D). Notably, blocking the type I IFN
response by treating the cells with JAK inhibitor generally
resulted in increased HBsAg secretion, as well as cccDNA pro-
duction, although in some donors (such as HD2), even JAK
inhibition was unable to promote the production of detectable
levels of cccDNA. Furthermore, the interdonor variation in in-
fection levels did not correlate with other established biomarkers
of hepatocyte function (Fig. S5). Collectively, these results sug-
gest that MPCCs support HBV infection in a hepatocyte donor-
dependent manner. Although technical factors implicated in
hepatocyte isolation and cryopreservation may play a role, it is
also possible that a divergence in genetically determined host
factors may underlie this variation.
iPSC-Derived iHeps as a Candidate HBV Host in Vitro. To overcome
the variability in HBV permissiveness observed among donors of
primary human hepatocytes, we considered options for generating
a physiologically relevant in vitro system on an isogenic background.
iPSCs are renewable, can be derived from a single donor, and re-
peatedly differentiated into iHeps that share features of human
hepatocytes (15, 16, 26) (Fig. S6A). To ascertain whether iHeps
might be permissive to HBV infection, we first investigated the
expression kinetics of NTCP during the course of iHep differenti-
ation. Using immunostaining, we observed that although NTCP was
barely detectable on day 15, it was readily detectable 3 d later and
increased throughout the remainder of the differentiation protocol
(Fig. S6B, Left). Consistent with the protein-expression findings,
quantitative analysis of NTCP mRNA levels also showed a gradual
increase throughout differentiation, although the level achieved in
day 20 differentiated iHeps remained less than that observed in
cryopreserved primary adult hepatocytes (Fig. S6B, Right).
In addition to the dependence on an entry receptor, iHeps
must also exhibit the capacity to support HBV transcription to
support replication. Thus, we assessed the earliest stage at which
differentiating iHeps achieved this milestone by transfecting
them with an HBV luciferase reporter construct (Fig. S6C).
Although the liver-enriched transcription factor HNF-4α, central
to the activation of the HBV transcriptional program (27), is
expressed early during iHep differentiation (22, 28) (Fig. S6A),
HBV transcriptional activity was not detected until day 18, after
which it continued to rise (Fig. S6C).
iHeps Support Productive HBV Infection During Late Stages of
Differentiation. To investigate whether iPSC-derived iHeps are
permissive to productive HBV infection, we incubated differ-
entiating iPSCs with HBV infectious serum and assayed for
markers of the viral life cycle. Analysis performed at 16 dpi
revealed signs of productive infection in fully differentiated
iHeps (day 20 of differentiation), but not in cells infected at
earlier stages of differentiation, as evidenced by 3.5-kb mRNA
expression, HBsAg secretion, and cccDNA accumulation (Fig. 4
A–C). To examine both the specificity and kinetics of HBV in-
fection of day 20 iHeps, we incubated cells with HBV infectious
serum with or without JAKi and the antiviral drug entecavir.
When analyzed over a 3-wk period, only JAKi-treated iHeps
maintained significant secretion of HBsAg over time, in contrast
to a rapid loss of HBsAg produced by vehicle-treated or ente-
cavir-treated cells (Fig. 4D). However, HBV DNA, both quan-
tified (Fig. S7) and also analyzed by Southern blot (showing
mainly relaxed circular replicative forms migrating at around 3.2
kb) (Fig. 4E), as well as HBV core protein (Fig. 4F) were
detected in day 20 iHeps, largely independent of JAK inhibition.
Given this discrepancy, we analyzed the effect of HBV infection
on innate immune activation in iHeps, where we detected in-
duction of many of the same ISGs that were observed in HBV-
infected MPCCs (Fig. 4G). However, most of the ISG transcripts
produced by infected iHeps were rarely elevated to the same
magnitude, with the exception of viperin, which was induced over
15-fold in day 20 iHeps, relative to day 7 iHeps, which were
Fig. 3. MPCCs as a platform for anti-HBV drug studies. (A) MPCCs treated
with DMSO or JAKi, with or without entecavir or IFN-β, were incubated with
HBV infectious serum for 24 h, followed by continued drug treatment every
2 d. Collected supernatants were analyzed for HBV DNA after 3 wk (Left),
and for secreted HBsAg at the indicated time points (Right); results are
expressed as a mean ± SEM, n = 3. (B) HBV-infected MPCCs treated with JAKi
were dosed with either IFN-β or entecavir from 7 to 16 dpi, when cell pellets
were analyzed for 3.5-kb mRNA expression relative to nonantiviral treated
cells (one cell pellet per condition, verified across multiple experiments; Left)
and for cccDNA, expressed as an average (per cell pellet) of duplicates ±
range (Right). Also at 16 dpi, medium (last changed at 14 dpi) was analyzed
for secreted HBV DNA, expressed as a mean ± SEM (n = 3) (Center). (C and D)
JAKi or DMSO-treated MPCCs bearing primary human hepatocytes from
different donors were incubated with HBV infectious serum and assayed at
16 dpi for HBsAg, expressed as average of duplicates, and cccDNA quanti-
fication, total copies per cell pellet. Dotted lines indicate limit of quantifi-
cation (qPCR) or cut-off (ELISA).
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essentially uninfected by HBV. Collectively, these results suggest
that iPSCs at advanced stages of the hepatic differentiation
program support productive HBV infection, which can be
maintained over a period of weeks with the addition of an innate
immune response inhibitor.
Discussion
In this study, we report HBV infection in two complementary pa-
tient-derived hepatocyte systems in which infection is limited by an
innate immune response, and demonstrate the utility of these sys-
tems for studying virus–host interactions. The establishment of two
complementary HBV model systems represents an opportunity to
tackle questions regarding major components of the viral entry
process and viral life cycle, including host factors underlying es-
tablishment and persistence of a nuclear cccDNA pool, the key viral
reservoir that leaves patients susceptible to viral reactivation (29).
The MPCC system uses micropatterned primary human hep-
atocytes cocultured with stromal fibroblasts, a format that en-
sures the prolonged viability and functionality of these delicate
cells (12). By comparing the HBV permissiveness of MPCCs to
that of cocultured cells seeded in a random format, we show that
the patterning provided by the MPCC format is essential to
maintaining productive infection for up to 3 wk. An advantage of
the MPCC system is its facility for interrogating the identity of
host factors responsible for the observed permissiveness, in that
cryopreserved donor cells that exhibit comparable hepatocyte
functions in culture but disparate permissiveness to HBV in-
fection can be subjected to systematic molecular analysis. In this
manner, candidate host-factor pathways and drug-targeting
strategies may be explored in vitro.
We can also leverage inherent strengths of the iHep system to
identify candidate essential host factors that confer HBV sensi-
tivity. In the differentiating populations, we observe that HBV
transcriptional activity increases over time, and can be overlaid
with the stepwise process of hepatocyte-specific factor acquisi-
tion. Thus far, our differentiation time-course data tracking both
NTCP expression and HBV promoter/enhancer element-driven
luciferase expression demonstrate that the up-regulation of both
entry factors and other transcription-related host factors are
essential for successful infection by HBV. We observe a tipping
point for permissiveness at around days 18–20 of the iHep dif-
ferentiation process, corresponding to a switch from a hepato-
blast-like phenotype to one resembling fetal hepatocytes. A
comparison of populations on either side of this time point may
identify candidate pathways, to be filtered based on findings from
the MPCC system, and interrogated via directed mutagenesis or
selective generation of iPSC lines from desired genotypes. In
addition, the stage-specific acquisition of permissiveness to hep-
atotropic pathogens may offer a novel method for assessing the
relative success of candidate in vitro differentiation protocols.
One important suite of host factors consists of the proteins
involved in the hepatocyte innate immune response, the role of
which in restricting HBV infection has been difficult to pin down
(7). Much of this debate has resulted from deficiencies in the
model systems used for HBV studies, because commonly used
hepatoma cell lines possess well-documented defects in innate
immune sensing and signal transduction (3, 4). In our systems,
the establishment of productive and long-lasting infection was
aided by inhibiting the innate immune response with inhibitors of
the JAK family or the signaling intermediate TBK1. However,
our data show that JAK inhibition boosted infection much more
in MPCCs than in day 20 differentiated iHeps, as evidenced by
the similar levels of viral replication achieved with and without
JAK inhibition in differentiated iHeps (Fig. 4). This difference
may be caused by the weaker induction of ISGs observed in
HBV-infected iHeps compared with MPCCs, reflecting differ-
ences in host innate immune response between fully differentiated
primary human hepatocytes and iPSC-induced hepatocyte-like
cells (30, 31). Still, the differential effect of JAK inhibition on
different markers of viral replication (e.g., large effects on HBsAg
secretion but minor effects on replicative intermediate formation)
observed in iHeps is not entirely clear and requires further study.
Our observation that innate immune activation restricts HBV
infection is consistent with studies showing that HBV can be
cleared from the liver in a cytokine-mediated, noncytotoxic
manner (25, 32), and that HBV replication is significantly re-
duced in chimpanzees chronically infected with HCV because of
the induction of the type I IFN response (33). In contrast to the
robust induction of ISGs in HBV-infected MPCCs, and to a lesser
extent in iHeps, no ISG response was observed in HBV-permissive
Fig. 4. HBV infection of iHeps is drug-sensitive and differentiation-
dependent. (A–C) iPSCs were differentiated in a stepwise fashion, treated with
JAKi and incubated with HBV infectious serum upon treatment at the in-
dicated days of the differentiation protocol. (A) At 16 dpi, HBV 3.5-kb mRNA
was quantified by qRT-PCR, shown relative to DMSO-treated cells infected at
day 10 of differentiation, and expressed as the mean ± SEM across two
separate experiments. (B) Also at 16 dpi, medium (last changed at 14 dpi)
was analyzed for secreted HBsAg (mean ± SEM, n = 3). (C) Agarose gel
separation of amplified cccDNA products (16 dpi) on a single gel with high-
(++) and low- (+) expression positive controls (size mismatch because of
slight curvature between distant lanes). (D) Differentiated iHeps (day 20 of
differentiation) treated as indicated were incubated with HBV infectious
serum, followed by HBsAg measurements in media, expressed as a mean ± SEM
(n = 3). (E and F). iPSCs were incubated with HBV infectious serum at the in-
dicated days of differentiation with DMSO or JAKi. (E) Southern blot of cellular
DNA extracted at 16 dpi (SI Materials and Methods) using an HBV-specific probe;
arrow indicates bands corresponding to HBV DNA (predicted to be relaxed, cir-
cular DNA at this size). (F) HBcAg immunofluorescent staining of DMSO- or JAKi-
treated 16-dpi iPSCs infected at day 15 and 20 of differentiation; (Scale bar, 50
μm.) (G) ISG mRNA expression by qRT-PCR of HBV-infected iHeps at 16 dpi,
normalized to the expression of HBV infected cells at day 7 of differentiation.
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HepG2 cells overexpressing NTCP. This finding emphasizes the
advantage of both MPCCs and iHeps over hepatoma cell lines and
traditional hepatocyte culture systems in the analysis of virus–host
interactions, in particular innate immune responses. A similar
induction of the type I IFN response accompanied by up-regula-
tion of ISGs was previously observed in HBV-permissive HepaRG
cells, but not in HepG2 cells upon induction of a baculovirus
expressing HBV (34). However, even in HepaRG cells, the
bipotential nature of the cells suggests an immature state in which
the innate immune axis may not be fully developed. Similarly, our
observation that iHeps display more modest, differentiation stage-
dependent ISG induction relative to MPCCs, may be explained by
the finding that the innate immune axis matures in concert with
the hepatic phenotype of differentiating iHeps (35). Thus, our
results support the model that the innate immune system plays
a role in HBV infection and suggests that HBV may be less of
a “stealth virus” than previously thought (36).
Notably, in the MPCC platform, we observed that a constant
fraction of around 25% of the cells were HBc-positive between
7 and 19 d postinfection. This absence of apparent viral spread
raises the possibility that viral production is not robust enough to
support reinfection, or that the rate of new infection is offset by viral
clearance from other cells. In addition, given the prolonged main-
tenance of normal hepatocyte function in the MPCC system, it is
not clear why levels of HBV surface antigen and DNA secretion
drop precipitously by 21 dpi. One possible explanation is that
a gradual reduction in host factors essential to the viral transcrip-
tion/replication machinery induces an eventual block at the level of
gene expression or replication. The observation that the cccDNA
level remains relatively stable even after the sharp decline in the
viral gene expression and replication raises the intriguing possibility
that these kinetics represent a switch from a more acute stage of
infection to one that is more chronic and low-level.
In summary, we show that MPCCs and pluripotent stem cell-
derived iHeps are both permissive to and support productive HBV
infection. We envision these platforms to be complementary, each
with their own advantages, and also each with the capacity to in-
form further optimization of the other. Thus, the combination of
our HBV infectious systems will open new avenues to more fully
characterize the HBV life cycle and its interaction with the host,
thereby promoting the identification of potential drug targets for
a disease infecting 400 million people globally.
Materials and Methods
The experimental conditions used to generate MPCCs, maintain iPSCs, and
differentiate iHeps have all been previously described (12, 15, 16, 19). For
HBV infection of MPCCs and iHeps, cultures were pretreated for 24 h with
dimethyl sulfoxide [0.01% (vol/vol)], JAKi (1 μM; EMD Millipore), TBK1 in-
hibitor (1 μM; EMD Millipore), IFN-β (1,000 U/mL; R&D Systems), or entecavir
(120 nM; Cayman Chemicals), as indicated, followed by infection with HBV+
patient plasma. Additional details are described in SI Materials and Methods,
including techniques used to assess HBV infection, such as total DNA, cccDNA,
RNA analysis, immunofluorescence, and ELISA for HBsAg and HBeAg.
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